[go: up one dir, main page]

NO20030034L - En kombinasjon av FBPase-inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes - Google Patents

En kombinasjon av FBPase-inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes

Info

Publication number
NO20030034L
NO20030034L NO20030034A NO20030034A NO20030034L NO 20030034 L NO20030034 L NO 20030034L NO 20030034 A NO20030034 A NO 20030034A NO 20030034 A NO20030034 A NO 20030034A NO 20030034 L NO20030034 L NO 20030034L
Authority
NO
Norway
Prior art keywords
diabetes
treatment
combination
agents useful
antidiabetic agents
Prior art date
Application number
NO20030034A
Other languages
English (en)
Other versions
NO20030034D0 (no
Inventor
Paul D Van Poelje
Mark D Erion
Toshihiko Fujiwara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20030034D0 publication Critical patent/NO20030034D0/no
Publication of NO20030034L publication Critical patent/NO20030034L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20030034A 2000-07-06 2003-01-03 En kombinasjon av FBPase-inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes NO20030034L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
PCT/US2001/021557 WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number Publication Date
NO20030034D0 NO20030034D0 (no) 2003-01-03
NO20030034L true NO20030034L (no) 2003-03-05

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030034A NO20030034L (no) 2000-07-06 2003-01-03 En kombinasjon av FBPase-inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (no)
JP (1) JP2004508297A (no)
KR (1) KR100854851B1 (no)
CN (2) CN100396283C (no)
AU (2) AU2001273271B2 (no)
BR (1) BR0112212A (no)
CA (1) CA2412142A1 (no)
CZ (1) CZ20035A3 (no)
HU (1) HUP0301830A3 (no)
IL (2) IL153513A0 (no)
MX (1) MXPA02012713A (no)
NO (1) NO20030034L (no)
NZ (1) NZ523227A (no)
PL (1) PL365779A1 (no)
RU (1) RU2328308C2 (no)
SK (1) SK62003A3 (no)
WO (1) WO2002003978A2 (no)
ZA (1) ZA200300044B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
PT1112275E (pt) 1998-09-09 2003-12-31 Metabasis Therapeutics Inc Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
CA2401706A1 (en) 2000-03-08 2001-09-13 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CN100350968C (zh) 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
WO2003057235A2 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CN1902196B (zh) 2003-12-26 2010-12-29 协和发酵麒麟株式会社 噻唑衍生物
CN101005847A (zh) * 2004-08-18 2007-07-25 症变治疗公司 果糖1,6－双磷酸酶的新颖噻唑类抑制剂
CA2590883A1 (en) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited Medicinal composition for treating diabetes
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
WO2008057933A2 (en) 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
TWI606848B (zh) * 2012-10-08 2017-12-01 Ｌｇ生命科學股份有限公司 包含格米列汀與美氟明的組合藥物及其製備方法
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114474T1 (de) * 1989-01-24 1994-12-15 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1998039343A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
US6107274A (en) * 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
PT1112275E (pt) * 1998-09-09 2003-12-31 Metabasis Therapeutics Inc Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
DK1143955T3 (da) * 1998-12-24 2005-11-14 Metabasis Therapeutics Inc En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
EP1741445B1 (en) * 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
MXPA02012713A (es) 2004-09-10
IL153513A0 (en) 2003-07-06
HUP0301830A3 (en) 2007-10-29
AU2001273271B2 (en) 2006-01-05
HUP0301830A2 (hu) 2003-11-28
IL153513A (en) 2014-07-31
CN100396283C (zh) 2008-06-25
WO2002003978A3 (en) 2003-10-16
RU2328308C2 (ru) 2008-07-10
NZ523227A (en) 2005-04-29
KR20030031952A (ko) 2003-04-23
PL365779A1 (en) 2005-01-10
CA2412142A1 (en) 2002-01-17
KR100854851B1 (ko) 2008-08-27
NO20030034D0 (no) 2003-01-03
CN1599612A (zh) 2005-03-23
WO2002003978A2 (en) 2002-01-17
EP1372660A2 (en) 2004-01-02
BR0112212A (pt) 2003-12-30
JP2004508297A (ja) 2004-03-18
ZA200300044B (en) 2004-05-06
SK62003A3 (en) 2003-09-11
CZ20035A3 (cs) 2003-05-14
AU7327101A (en) 2002-01-21
CN101301294A (zh) 2008-11-12

Similar Documents

Publication Publication Date Title
NO20030034D0 (no) En kombinasjon av FBPase inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
IS6700A (is) Meðferðarblanda CETP hindra og atórvastatíns
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
NO20022656L (no) Caspaseinhibitorer og anvendelse derav
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
CY2008010I1 (el) Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες
NO20020343D0 (no) Kaspase-inhibitorer og anvendelse derav
NO20042229L (no) Type 4-fosfodiestemseinhibitorer og anvendelse derav
NO20016314D0 (no) Blandinger og fremgangsmåte for oljefeltapplikasjoner
NO20011114D0 (no) FremgangsmÕte og anordning for brudd-/gruspakker
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20022086L (no) Antidiabetisk formulering og fremgangsmåte
NO20014823L (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
NO20011964L (no) Brönnbehandlingsfluider og fremgangsmåter for anvendelse derav
DK1339292T3 (da) Sammensætning og fremgangsmåde
PL374598A1 (en) Caspase inhibitors and uses thereof
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
EP1337255A4 (en) USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH
DK1322597T3 (da) Fremgangsmåde og intermediære
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
DE60106740D1 (de) Hydrazid und alkoxyamid angiogeneseinhibitoren
NO20026065L (no) Prosesser for måling av dinofysistoksin og av yessotoksin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application